Serum neurofilament light chain (sNfL) levels in MS are associated with inflammatory activity and less clearly with disability. In this touchNEUROLOGY interview, we caught up with Dr Georgina Arrambide (Cemcat, Vall d´Hebron University Hospital, Barcelona, Spain) to discuss the findings from a study investigating sNfL Z score cut-offs in MS, and the impact on diagnosis specificity and predicting disability milestones.
The abstract entitled ‘Predictive sNfL Z score cut-offs in MS vary depending on the outcome and may help increase diagnostic specificity at the expense of sensitivity in CIS patients not fulfilling McDonald MS at baseline’ (Abstract #O177) was presented at ECTRIMS, 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 26 – 28 October 2022, Amsterdam, the Netherlands.
- What is known about the significance of serum neurofilament light chain (sNFL) levels in MS? (0:17)
- What were the aims, methodology and patient population of your study? (0:46)
- What were the findings of the study in terms of diagnosis specificity and predicting disability milestones? (2:47)
- What questions remained unanswered and what future studies are planned? (4:22)
Disclosures: Georgina Arrambide receives grant/research support from Instituto de Salud Carlos III (FIS PI19/01570); is on the advisory board for Horizon Therapeutics, Roche, Sanofi and Merck; and receives honoraria/honorarium from Novartis, Roche, and ECTRIMS.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ECTRIMS 2022
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!